US Patent Issued to Bristol-Myers Squibb on Nov. 25 for "Ipilimumab variants with enhanced specificity for binding at low pH" (California, New Jersey Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,478,674, issued on Nov. 25, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Ipilimumab variants with enhanced specificity for binding at low pH" was invented by Peter Sung Keun Lee (Millbrae, Calif.), Pavel Strop (San Mateo, Calif.), Arvind Rajpal (San Francisco), Olafur S. Gudmundsson (West Windsor, N.J.) and Pradyot Nandi (Haskell, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides variant forms of anti-CTLA-4 antibodies, such as ipilimumab, that preferentially bind to CTLA-4 at low pH. Such antibody variants exhibit preferential activity in the tumor microenvironment, an enhanced ratio of anti-tumor respon...